Candriam S.C.A. Travere Therapeutics, Inc. Transaction History
Candriam S.C.A.
- $16.8 Billion
- Q2 2025
A detailed history of Candriam S.C.A. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 512,681 shares of TVTX stock, worth $15.2 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
512,681
Previous 534,072
4.01%
Holding current value
$15.2 Million
Previous $9.57 Million
20.72%
% of portfolio
0.05%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding TVTX
# of Institutions
235Shares Held
103MCall Options Held
1.71MPut Options Held
401K-
Janus Henderson Group PLC London, X09.54MShares$283 Million0.07% of portfolio
-
Armistice Capital, LLC New York, NY8.88MShares$263 Million2.3% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$227 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$178 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C35.1MShares$151 Million0.1% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.9B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...